HPRL
MCID: HYP020
MIFTS: 60

Hyperprolactinemia (HPRL) malady

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Reproductive diseases, Metabolic diseases

Aliases & Classifications for Hyperprolactinemia

Aliases & Descriptions for Hyperprolactinemia:

Name: Hyperprolactinemia 54 12 24 66 52 42 14 69
Chiari-Frommel Syndrome 12 50 42 69
Hyperprolactinaemia 12 29
Hprl 24 66
Familial Isolated Prolactin Receptor Deficiency 56
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 56

Characteristics:

Orphanet epidemiological data:

56
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

HPO:

32
hyperprolactinemia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 615555
Disease Ontology 12 DOID:12700
ICD10 33 E22.1
NCIt 47 C113168
Orphanet 56 ORPHA397685
ICD10 via Orphanet 34 E22.1
MedGen 40 C0020514

Summaries for Hyperprolactinemia

OMIM : 54 Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result... (615555) more...

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to endometriosis and ahumada del castillo syndrome, and has symptoms including osteopenia, osteoporosis and infertility. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and endocrine/exocrine gland

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

UniProtKB/Swiss-Prot : 66 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
id Related Disease Score Top Affiliating Genes
1 endometriosis 29.8 GNRH1 PRL PRLR
2 ahumada del castillo syndrome 11.3
3 galactorrhoea-hyperprolactinaemia 11.0
4 mccune-albright syndrome, somatic, mosaic 10.8
5 grin2a-related speech disorders and epilepsy 10.3 GH1 PRL
6 gershoni-baruch syndrome 10.3 PRL TRH
7 rhinoscleroma 10.3 DRD2 PRL
8 glaucoma, hereditary adult type 1a 10.3 GH1 PRL
9 diverticulitis 10.3 GNRH1 PRL
10 macrocephaly, benign familial 10.2 GH1 POMC
11 pfeiffer rockelein syndrome 10.2 DRD2 PRL
12 endometrial mixed adenocarcinoma 10.2 POMC TRH
13 wheat allergy 10.2 POMC PRL
14 pancreatic colloid cystadenoma 10.2 POMC PRL
15 ornithosis 10.2 DRD2 PRL
16 microtia, hearing impairment, and cleft palate 10.2 GH1 IGF1
17 spondylometaphyseal dysplasia, megarbane-dagher-melike type 10.2 GH1 IGF1
18 vertebral artery occlusion 10.1 GNRH1 POMC PRL
19 pemphigus vegetans 10.1 GH1 SST
20 osseous heteroplasia, progressive 10.1 GH1 IGF1 PRL
21 kindler syndrome 10.1 GNRH1 POMC PRL
22 burning mouth syndrome type 3 10.1 POMC SST
23 renal hypoplasia, bilateral 10.1 POMC SST
24 transmitted_by 10.1 DRD2 POMC PRL
25 sphingolipidosis 10.1 GNRH1 POMC PRL
26 necrobiosis lipoidica 10.1 IGF1 PRL PRLR
27 water-clear cell adenoma 10.1 POMC SST
28 astroblastoma 10.1 GNRH1 POMC PRL
29 spondylolysis 10.1 GNRH1 POMC PRL
30 avoidant personality disorder 10.1 GNRH1 POMC PRL
31 haverhill fever 10.1 GNRH1 IGF1 PRL
32 epileptic encephalopathy, early infantile, 24 10.1 GH1 IGF1
33 dacryoadenitis 10.1 IGF1 POMC PRL
34 epidural spinal canal meningioma 10.1 GNRH1 IGF1 PRL
35 critical congenital heart disease 10.1 GH1 GNRH1 IGF1
36 bone benign neoplasm 10.1 IGF1 POMC PRL
37 primary effusion lymphoma 10.1 GH1 GNRH1 IGF1
38 pinguecula 10.1 GNRH1 IGF1 PRL
39 schizophrenia 10.1
40 cerebral hemisphere lipoma 10.1 GH1 PRL SST
41 uterine ligament cancer 10.1 IGF1 SST
42 primary biliary cirrhosis 10.1 GNRH1 IGF1 PRL
43 lung occult small cell carcinoma 10.1 DRD2 PRL SST
44 breast secretory carcinoma 10.1 POMC SST
45 suppurative periapical periodontitis 10.1 DRD2 IGF1 POMC
46 hypogonadism cardiomyopathy 10.1 GH1 POMC PTHLH
47 congenital tricuspid stenosis 10.1 GH1 POMC PRL TRH
48 adult i blood group with or without congenital cataract 10.0 GH1 POMC PRL TRH
49 nonparalytic poliomyelitis 10.0 POMC PRL SST
50 merkel cell carcinoma 10.0 POMC PRL SST

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Symptoms by clinical synopsis from OMIM:

615555

Clinical features from OMIM:

615555

Human phenotypes related to Hyperprolactinemia:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 56 32 Occasional (29-5%) HP:0000938
2 osteoporosis 56 32 Occasional (29-5%) HP:0000939
3 infertility 56 32 Frequent (79-30%) HP:0000789
4 menorrhagia 56 32 Occasional (29-5%) HP:0000132
5 galactorrhea 56 32 Very frequent (99-80%) HP:0100829
6 female hypogonadism 56 32 Occasional (29-5%) HP:0000134
7 amenorrhea 56 32 Frequent (79-30%) HP:0000141
8 oligomenorrhea 56 32 Very frequent (99-80%) HP:0000876
9 hemorrhagic ovarian cyst 56 32 Frequent (79-30%) HP:0012886
10 prolactin excess 32 HP:0000870

GenomeRNAi Phenotypes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.74 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.74 GAL IGF1 POMC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.74 IGF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.74 GAL
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.74 POMC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.74 IGF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.74 GAL
8 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.74 GAL
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.74 IGF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.74 IGF1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.74 IGF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.74 IGF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 GAL
14 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.74 IGF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.74 IGF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.74 GAL
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.74 IGF1 POMC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.74 POMC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 GAL
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 GAL
21 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.74 POMC
22 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.74 POMC
23 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.74 IGF1

MGI Mouse Phenotypes related to Hyperprolactinemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.13 PRLR PTHLH TRH VIP DRD2 GAL
2 homeostasis/metabolism MP:0005376 10.11 DRD2 GAL GNRH1 IGF1 POMC PRL
3 behavior/neurological MP:0005386 10.06 DRD2 GAL POMC PRL PRLR PTHLH
4 growth/size/body region MP:0005378 10.06 DRD2 GAL GNRH1 IGF1 POMC PRLR
5 immune system MP:0005387 9.92 DRD2 GNRH1 IGF1 POMC PRL PTHLH
6 adipose tissue MP:0005375 9.88 IGF1 POMC PRLR PTHLH DRD2
7 integument MP:0010771 9.86 POMC PRL PRLR PTHLH DRD2 GAL
8 nervous system MP:0003631 9.65 DRD2 GAL GNRH1 IGF1 POMC PRL
9 neoplasm MP:0002006 9.63 DRD2 GNRH1 IGF1 POMC PRL PRLR
10 reproductive system MP:0005389 9.23 DRD2 GAL GNRH1 IGF1 PRL PRLR

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Cabergoline Approved Phase 4 81409-90-7 54746
5
Quinagolide Approved Phase 4 97805-50-0, 87056-78-8 105105
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
7
Amantadine Approved Phase 4 768-94-5 2130
8 Antipsychotic Agents Phase 4,Phase 3,Phase 2
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2
11 Tranquilizing Agents Phase 4,Phase 3,Phase 2
12 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Dopamine Antagonists Phase 4,Phase 3
14 Dopamine D2 Receptor Antagonists Phase 4
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Paliperidone Palmitate Phase 4
17
Serotonin Phase 4,Phase 3 50-67-9 5202
18 Serotonin 5-HT2 Receptor Antagonists Phase 4
19 Serotonin Agents Phase 4,Phase 3
20 Serotonin Antagonists Phase 4,Phase 3
21 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
22 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
25 Estradiol 17 beta-cypionate Phase 4
26 Estradiol 3-benzoate Phase 4
27 Estradiol valerate Phase 4 979-32-8
28 Polyestradiol phosphate Phase 4
29 Analgesics Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Anti-Infective Agents Phase 4
32 Antiviral Agents Phase 4
33
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
34 Hormone Antagonists Phase 3,Phase 2
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
36 Quetiapine Fumarate Phase 3 111974-72-2
37
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 5095 497540
38 Pharmaceutical Solutions Phase 2
39 Autonomic Agents Phase 1, Phase 2
40 Protective Agents Phase 1, Phase 2
41 Licorice Nutraceutical Phase 2
42
Calcium carbonate Approved 471-34-1
43
Levodopa Approved 59-92-7 6047
44
Bevacizumab Approved, Investigational 216974-75-3
45
Haloperidol Approved 52-86-8 3559
46
Olanzapine Approved, Investigational 132539-06-1 4585
47
Epinephrine Approved, Vet_approved 51-43-4 5816
48
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
49 Hypoglycemic Agents
50 insulin

Interventional clinical trials:

(show all 35)
id Name Status NCT ID Phase
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4
3 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4
4 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4
5 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4
7 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4
8 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4
9 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated NCT00975611 Phase 4
10 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3
11 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed NCT00600756 Phase 3
12 Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Completed NCT01852331 Phase 2
13 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2
14 Administration of Kisspeptin in Patients With Hyperprolactinemia Not yet recruiting NCT02956447 Phase 2
15 Administration of Kisspeptin to Subjects With Reproductive Disorders Recruiting NCT00914823 Phase 1
16 Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Unknown status NCT00699530
17 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia Unknown status NCT02013232
18 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584
19 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine Completed NCT00952757
20 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383
21 Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Completed NCT01338298
22 Characterization of Macroprolactinemia Completed NCT00436111
23 The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women Completed NCT01117272
24 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Completed NCT01270711
25 Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Completed NCT02098668
26 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events Completed NCT01052948
27 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function Completed NCT00973557
28 Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy Completed NCT00399776
29 Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents Completed NCT00573716
30 Prevalence of Pregnancy in Polycystic Ovary Syndrome Completed NCT03157921
31 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
32 Assessing Fertility Potential in Female Cancer Survivors Recruiting NCT01143844
33 Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. Active, not recruiting NCT02092129
34 Pituitary Function and Spontaneous Intracranial Hypotension Active, not recruiting NCT02603549
35 TSH And AMH in Infertile Women Enrolling by invitation NCT02710175

Search NIH Clinical Center for Hyperprolactinemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperprolactinemia

Genetic Tests for Hyperprolactinemia

Genetic tests related to Hyperprolactinemia:

id Genetic test Affiliating Genes
1 Hyperprolactinemia 29 24 PRLR

Anatomical Context for Hyperprolactinemia

MalaCards organs/tissues related to Hyperprolactinemia:

39
Pituitary, Bone, Breast, Testes, Thyroid, Prostate, Ovary

Publications for Hyperprolactinemia

Articles related to Hyperprolactinemia:

(show top 50) (show all 712)
id Title Authors Year
1
Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach. ( 28440197 )
2017
2
Re: Myocardial Recovery in Peripartum Cardiomyopathy after Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28114195 )
2017
3
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( 28372526 )
2017
4
Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat. ( 28259983 )
2017
5
Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. ( 28437810 )
2017
6
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
7
Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. ( 27671881 )
2017
8
Erratum to: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. ( 27854004 )
2017
9
Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. ( 28236625 )
2017
10
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. ( 28396166 )
2017
11
Occurrence of hyperprolactinemia in children with subclinical hypothyroidism. ( 28529200 )
2017
12
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. ( 28235557 )
2017
13
Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder. ( 28273980 )
2017
14
Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. ( 27773859 )
2017
15
Re: Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28169846 )
2017
16
The central mechanism of risperidone-induced hyperprolactinemia. ( 28336493 )
2017
17
Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia. ( 28320278 )
2017
18
Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on BIVAD. ( 27748657 )
2017
19
Cabergoline for hyperprolactinemia: getting to the heart of it. ( 28260205 )
2017
20
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. ( 27709470 )
2017
21
Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder. ( 27335526 )
2016
22
Rheumatoid Arthritis, Kartagener's Syndrome, and Hyperprolactinemia: Who Started It? ( 26904347 )
2016
23
Factors Influencing Disconnection Hyperprolactinemia and Reversal of Serum Prolactin after Pituitary Surgery in a Non-Functioning Pituitary Macroadenoma. ( 27540328 )
2016
24
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients. ( 27639124 )
2016
25
Pregabalin-induced hyperprolactinemia in a patient with fibromyalgia: A case report. ( 28275758 )
2016
26
Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. ( 27774730 )
2016
27
HYPERTHYROIDISM AND HYPERPROLACTINEMIA, IS THERE ANY ASSOCIATION? ( 27540882 )
2016
28
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. ( 26921057 )
2016
29
Hyperprolactinemia and Hirsutism in Patients Without Polycystic Ovary Syndrome. ( 27625565 )
2016
30
Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. ( 27776952 )
2016
31
Gynecomastia and Hyperprolactinemia Secondary to Advanced Allergic Fungal Rhinosinusitis in a Pediatric Patient. ( 26768883 )
2016
32
Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. ( 27621638 )
2016
33
A New Method of Using Polyethylene Glycol (PEG) Precipitation of Macroprolactin to Detect Genuine Hyperprolactinemia. ( 27219457 )
2016
34
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. ( 28086010 )
2016
35
Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. ( 27245604 )
2016
36
18I^-Glycyrrhetinic Acid, a Novel Naturally Derived Agent, Suppresses Prolactin Hyperactivity and Reduces Antipsychotic-Induced Hyperprolactinemia in In Vitro and In Vivo Models. ( 27161375 )
2016
37
Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. ( 27455388 )
2016
38
Chronic hyperprolactinemia evoked by disruption of lactotrope dopamine D2 receptors impacts on liver and adipocyte genes related to glucose and insulin balance. ( 27802964 )
2016
39
Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. ( 27438182 )
2016
40
Effects of pterostilbene on treating hyperprolactinemia and related mechanisms. ( 27508025 )
2016
41
Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. ( 27473607 )
2016
42
Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. ( 26822064 )
2016
43
The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. ( 26858210 )
2016
44
Hyperprolactinemia Secondary to Pituitary Microadenoma versus Haloperidol-A Diagnostic Enigma: A Case Report and Brief Review. ( 27440143 )
2016
45
Clinical profile of hyperprolactinemia. ( 27727650 )
2016
46
Effect of hyperprolactinemia on PRL-receptor expression and activation of Stat and Mapk cell signaling in the prostate of long-term sexually-active rats. ( 26873413 )
2016
47
How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment. ( 27433851 )
2016
48
Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline. ( 27042412 )
2016
49
Hyperprolactinemia induced by hCG leads to metabolic disturbances in female mice. ( 27154336 )
2016
50
Association between Hyperprolactinemia and Granulomatous Mastitis. ( 26705962 )
2016

Variations for Hyperprolactinemia

UniProtKB/Swiss-Prot genetic disease variations for Hyperprolactinemia:

66
id Symbol AA change Variation ID SNP ID
1 PRLR p.His212Arg VAR_070895 rs398122522

ClinVar genetic disease variations for Hyperprolactinemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh37 Chromosome 5, 35070276: 35070276

Expression for Hyperprolactinemia

Search GEO for disease gene expression data for Hyperprolactinemia.

Pathways for Hyperprolactinemia

Pathways related to Hyperprolactinemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 DRD2 GAL GNRH1 IGF1 POMC PTHLH
2
Show member pathways
12.59 DRD2 GAL GH1 GNRH1 POMC PRL
3 12.09 GH1 IGF1 PRL PRLR
4
Show member pathways
11.87 GH1 IGF1 POMC
5
Show member pathways
11.82 GH1 PRL PRLR
6 11.71 POMC PTHLH VIP
7 11.62 GH1 IGF1 PRLR
8 11.14 GH1 IGF1 PTHLH
9
Show member pathways
10.95 POMC TRH
10
Show member pathways
10.74 GH1 PRL PRLR

GO Terms for Hyperprolactinemia

Cellular components related to Hyperprolactinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 GAL GH1 GNRH1 IGF1 POMC PTHLH
2 secretory granule GO:0030141 9.46 GAL POMC PRL TRH
3 extracellular region GO:0005576 9.36 GAL GH1 GNRH1 IGF1 POMC PRL
4 endosome lumen GO:0031904 9.13 GH1 PRL PRLR

Biological processes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.84 IGF1 PRL PTHLH VIP
2 regulation of gene expression GO:0010468 9.73 GNRH1 IGF1 PTHLH
3 response to drug GO:0042493 9.71 DRD2 GAL PRL SST
4 response to organic cyclic compound GO:0014070 9.65 GNRH1 PRL TRH
5 negative regulation of cell proliferation GO:0008285 9.65 DRD2 GAL GNRH1 PTHLH SST
6 adult walking behavior GO:0007628 9.55 DRD2 TRH
7 female pregnancy GO:0007565 9.54 GNRH1 PRL PTHLH
8 regulation of multicellular organism growth GO:0040014 9.52 IGF1 PRL
9 positive regulation of receptor internalization GO:0002092 9.51 DRD2 GH1
10 positive regulation of JAK-STAT cascade GO:0046427 9.49 GH1 PRL
11 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.46 GH1 IGF1
12 response to ethanol GO:0045471 9.46 DRD2 GNRH1 PRL TRH
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 IGF1
14 cell-cell signaling GO:0007267 9.35 GNRH1 POMC PTHLH SST TRH
15 ovulation cycle GO:0042698 9.32 GNRH1 PRL
16 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.8 GH1 PRL PRLR

Molecular functions related to Hyperprolactinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.32 GAL GH1 GNRH1 IGF1 POMC PRL
2 prolactin receptor binding GO:0005148 9.16 GH1 PRL
3 neuropeptide hormone activity GO:0005184 9.13 GAL TRH VIP

Sources for Hyperprolactinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....